286 related articles for article (PubMed ID: 28174173)
1. The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function.
Wan L; Chen M; Cao J; Dai X; Yin Q; Zhang J; Song SJ; Lu Y; Liu J; Inuzuka H; Katon JM; Berry K; Fung J; Ng C; Liu P; Song MS; Xue L; Bronson RT; Kirschner MW; Cui R; Pandolfi PP; Wei W
Cancer Discov; 2017 Apr; 7(4):424-441. PubMed ID: 28174173
[TBL] [Abstract][Full Text] [Related]
2. Anaphase-Promoting Complex Adaptor FZR1/CDH1 Blocks BRAF Signaling Both by Targeting BRAF for Proteolytic Degradation and by Disrupting BRAF Dimerization.
Zhang C; Bollag G
Cancer Discov; 2017 Apr; 7(4):356-358. PubMed ID: 28373167
[TBL] [Abstract][Full Text] [Related]
3. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.
Bhatt KV; Spofford LS; Aram G; McMullen M; Pumiglia K; Aplin AE
Oncogene; 2005 May; 24(21):3459-71. PubMed ID: 15735667
[TBL] [Abstract][Full Text] [Related]
4. Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis.
Han T; Jiang S; Zheng H; Yin Q; Xie M; Little MR; Yin X; Chen M; Song SJ; Beg AA; Pandolfi PP; Wan L
Nat Commun; 2019 Aug; 10(1):3716. PubMed ID: 31420536
[TBL] [Abstract][Full Text] [Related]
5. Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling.
Adamopoulos C; Ahmed TA; Tucker MR; Ung PMU; Xiao M; Karoulia Z; Amabile A; Wu X; Aaronson SA; Ang C; Rebecca VW; Brown BD; Schlessinger A; Herlyn M; Wang Q; Shaw DE; Poulikakos PI
Cancer Discov; 2021 Jul; 11(7):1716-1735. PubMed ID: 33568355
[TBL] [Abstract][Full Text] [Related]
6. Rb and FZR1/Cdh1 determine CDK4/6-cyclin D requirement in C. elegans and human cancer cells.
The I; Ruijtenberg S; Bouchet BP; Cristobal A; Prinsen MB; van Mourik T; Koreth J; Xu H; Heck AJ; Akhmanova A; Cuppen E; Boxem M; Muñoz J; van den Heuvel S
Nat Commun; 2015 Jan; 6():5906. PubMed ID: 25562820
[TBL] [Abstract][Full Text] [Related]
7. K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling.
Yin Q; Han T; Fang B; Zhang G; Zhang C; Roberts ER; Izumi V; Zheng M; Jiang S; Yin X; Kim M; Cai J; Haura EB; Koomen JM; Smalley KSM; Wan L
Nat Commun; 2019 Apr; 10(1):1870. PubMed ID: 31015455
[TBL] [Abstract][Full Text] [Related]
8. Cdk5-mediated inhibition of APC/C-Cdh1 switches on the cyclin D1-Cdk4-pRb pathway causing aberrant S-phase entry of postmitotic neurons.
Veas-Pérez de Tudela M; Maestre C; Delgado-Esteban M; Bolaños JP; Almeida A
Sci Rep; 2015 Dec; 5():18180. PubMed ID: 26658992
[TBL] [Abstract][Full Text] [Related]
9. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
10. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
[TBL] [Abstract][Full Text] [Related]
11. PRL-3 Promotes Ubiquitination and Degradation of AURKA and Colorectal Cancer Progression via Dephosphorylation of FZR1.
Zhang C; Qu L; Lian S; Meng L; Min L; Liu J; Song Q; Shen L; Shou C
Cancer Res; 2019 Mar; 79(5):928-940. PubMed ID: 30498084
[TBL] [Abstract][Full Text] [Related]
12. Regulation of APC(Cdh1) E3 ligase activity by the Fbw7/cyclin E signaling axis contributes to the tumor suppressor function of Fbw7.
Lau AW; Inuzuka H; Fukushima H; Wan L; Liu P; Gao D; Sun Y; Wei W
Cell Res; 2013 Jul; 23(7):947-61. PubMed ID: 23670162
[TBL] [Abstract][Full Text] [Related]
13. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
14. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
Heard JJ; Phung I; Potes MI; Tamanoi F
BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
[TBL] [Abstract][Full Text] [Related]
15. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
16. The E3 ligase APC/C(Cdh1) promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth.
Cao J; Dai X; Wan L; Wang H; Zhang J; Goff PS; Sviderskaya EV; Xuan Z; Xu Z; Xu X; Hinds P; Flaherty KT; Faller DV; Goding CR; Wang Y; Wei W; Cui R
Sci Signal; 2015 Sep; 8(392):ra87. PubMed ID: 26329581
[TBL] [Abstract][Full Text] [Related]
17. alphaB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells.
Hu R; Aplin AE
Pigment Cell Melanoma Res; 2010 Apr; 23(2):201-9. PubMed ID: 20067552
[TBL] [Abstract][Full Text] [Related]
18. Identification of the APC/C co-factor FZR1 as a novel therapeutic target for multiple myeloma.
Crawford LJ; Anderson G; Johnston CK; Irvine AE
Oncotarget; 2016 Oct; 7(43):70481-70493. PubMed ID: 27655696
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism.
Sánchez-Hernández I; Baquero P; Calleros L; Chiloeches A
Cancer Lett; 2012 Jan; 314(2):244-55. PubMed ID: 22056813
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation of the Anaphase Promoting Complex activator FZR1/CDH1 is required for Meiosis II entry in mouse male germ cell.
Tanno N; Kuninaka S; Fujimura S; Takemoto K; Okamura K; Takeda N; Araki K; Araki M; Saya H; Ishiguro KI
Sci Rep; 2020 Jun; 10(1):10094. PubMed ID: 32572094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
